An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

V. Grunwald; P.I. Karakiewicz; [No Value] et al; G. Groenewegen; I. Bodrogi; [No Value] REACT Study Group

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

V. Grunwald
, P.I. Karakiewicz
, [No Value] et al
, G. Groenewegen
, I. Bodrogi
, [No Value] REACT Study Group

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	324-332
Number of pages	9
Journal	European Journal of Cancer
Volume	48
Issue number	3
Publication status	Published - 2012

Cite this

Grunwald, V., Karakiewicz, P. I., et al, N. V., Groenewegen, G., Bodrogi, I., & REACT Study Group, N. V. (2012). An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 48(3), 324-332.

Grunwald, V. ; Karakiewicz, P.I. ; et al, [No Value] et al. / An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. In: European Journal of Cancer. 2012 ; Vol. 48, No. 3. pp. 324-332.

@article{10ac46e404b041f8a39301d7ede31d02,

title = "An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.",

author = "V. Grunwald and P.I. Karakiewicz and \{et al\}, \{[No Value]\} and G. Groenewegen and I. Bodrogi and \{REACT Study Group\}, \{[No Value]\}",

year = "2012",

language = "English",

volume = "48",

pages = "324--332",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "3",

}

Grunwald, V, Karakiewicz, PI, et al, NV, Groenewegen, G, Bodrogi, I & REACT Study Group, NV 2012, 'An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.', European Journal of Cancer, vol. 48, no. 3, pp. 324-332.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. / Grunwald, V.; Karakiewicz, P.I.; et al, [No Value] et al.
In: European Journal of Cancer, Vol. 48, No. 3, 2012, p. 324-332.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

AU - Grunwald, V.

AU - Karakiewicz, P.I.

AU - et al, [No Value]

AU - Groenewegen, G.

AU - Bodrogi, I.

AU - REACT Study Group, [No Value]

PY - 2012

Y1 - 2012

M3 - Article

SN - 0959-8049

VL - 48

SP - 324

EP - 332

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 3

ER -

Grunwald V, Karakiewicz PI, et al NV, Groenewegen G, Bodrogi I, REACT Study Group NV. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer. 2012;48(3):324-332.